• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床实践指南:注意缺陷/多动障碍儿童的诊断与评估。美国儿科学会。

Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics.

出版信息

Pediatrics. 2000 May;105(5):1158-70. doi: 10.1542/peds.105.5.1158.

DOI:10.1542/peds.105.5.1158
PMID:10836893
Abstract

This clinical practice guideline provides recommendations for the assessment and diagnosis of school-aged children with attention-deficit/hyperactivity disorder (ADHD). This guideline, the first of 2 sets of guidelines to provide recommendations on this condition, is intended for use by primary care clinicians working in primary care settings. The second set of guidelines will address the issue of treatment of children with ADHD. The Committee on Quality Improvement of the American Academy of Pediatrics selected a committee composed of pediatricians and other experts in the fields of neurology, psychology, child psychiatry, development, and education, as well as experts from epidemiology and pediatric practice. In addition, this panel consists of experts in education and family practice. The panel worked with Technical Resources International, Washington, DC, under the auspices of the Agency for Healthcare Research and Quality, to develop the evidence base of literature on this topic. The resulting evidence report was used to formulate recommendations for evaluation of the child with ADHD. Major issues contained within the guideline address child and family assessment; school assessment, including the use of various rating scales; and conditions seen frequently among children with ADHD. Information is also included on the use of current diagnostic coding strategies. The deliberations of the committee were informed by a systematic review of evidence about prevalence, coexisting conditions, and diagnostic tests. Committee decisions were made by consensus where definitive evidence was not available. The committee report underwent review by sections of the American Academy of Pediatrics and external organizations before approval by the Board of Directors. The guideline contains the following recommendations for diagnosis of ADHD: 1) in a child 6 to 12 years old who presents with inattention, hyperactivity, impulsivity, academic underachievement, or behavior problems, primary care clinicians should initiate an evaluation for ADHD; 2) the diagnosis of ADHD requires that a child meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria; 3) the assessment of ADHD requires evidence directly obtained from parents or caregivers regarding the core symptoms of ADHD in various settings, the age of onset, duration of symptoms, and degree of functional impairment; 4) the assessment of ADHD requires evidence directly obtained from the classroom teacher (or other school professional) regarding the core symptoms of ADHD, duration of symptoms, degree of functional impairment, and associated conditions; 5) evaluation of the child with ADHD should include assessment for associated (coexisting) conditions; and 6) other diagnostic tests are not routinely indicated to establish the diagnosis of ADHD but may be used for the assessment of other coexisting conditions (eg, learning disabilities and mental retardation). This clinical practice guideline is not intended as a sole source of guidance in the evaluation of children with ADHD. Rather, it is designed to assist primary care clinicians by providing a framework for diagnostic decisionmaking. It is not intended to replace clinical judgment or to establish a protocol for all children with this condition and may not provide the only appropriate approach to this problem.

摘要

本临床实践指南针对学龄期注意力缺陷多动障碍(ADHD)儿童的评估和诊断提供了建议。本指南是关于该病症的两套指南中的第一套,供在基层医疗环境中工作的基层医疗临床医生使用。第二套指南将涉及ADHD儿童的治疗问题。美国儿科学会质量改进委员会挑选了一个由儿科医生以及神经学、心理学、儿童精神病学、发育和教育领域的其他专家,还有流行病学和儿科实践方面的专家组成的委员会。此外,该小组还包括教育和家庭医疗方面的专家。该小组在美国医疗保健研究与质量局的支持下,与华盛顿特区的国际技术资源公司合作,建立了关于该主题的文献证据库。所得的证据报告被用于制定对ADHD儿童进行评估的建议。该指南涵盖的主要问题包括儿童及家庭评估;学校评估,包括各种评定量表的使用;以及ADHD儿童中常见的病症。其中还包括有关当前诊断编码策略使用的信息。委员会的审议工作以对患病率、共存病症和诊断测试的证据进行系统综述为依据。在没有确凿证据的情况下,委员会通过共识做出决定。委员会报告在获得董事会批准之前,经过了美国儿科学会各部门和外部组织的审查。该指南包含以下ADHD诊断建议:1)对于出现注意力不集中、多动、冲动、学业成绩不佳或行为问题的6至12岁儿童,基层医疗临床医生应启动对ADHD的评估;2)ADHD的诊断要求儿童符合《精神障碍诊断与统计手册》第四版标准;3)ADHD的评估需要直接从父母或照料者处获取关于ADHD在各种环境中的核心症状、起病年龄、症状持续时间和功能损害程度的证据;4)ADHD的评估需要直接从课堂教师(或其他学校专业人员)处获取关于ADHD的核心症状、症状持续时间、功能损害程度和相关病症的证据;5)对ADHD儿童的评估应包括对相关(共存)病症的评估;6)通常并不常规进行其他诊断测试来确诊ADHD,但可用于评估其他共存病症(如学习障碍和智力迟钝)。本临床实践指南并非ADHD儿童评估的唯一指导来源。相反,它旨在通过提供诊断决策框架来协助基层医疗临床医生。它无意取代临床判断,也不是为所有患有该病症的儿童制定方案,可能也不是解决此问题的唯一恰当方法。

相似文献

1
Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics.临床实践指南:注意缺陷/多动障碍儿童的诊断与评估。美国儿科学会。
Pediatrics. 2000 May;105(5):1158-70. doi: 10.1542/peds.105.5.1158.
2
Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.兴奋剂和非兴奋剂药物治疗注意缺陷多动障碍和癫痫患者。
Cochrane Database Syst Rev. 2022 Jul 13;7(7):CD013136. doi: 10.1002/14651858.CD013136.pub2.
3
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
4
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.用于治疗儿童和青少年注意力缺陷多动障碍(ADHD)的哌甲酯——非随机研究中不良事件的评估
Cochrane Database Syst Rev. 2018 May 9;5(5):CD012069. doi: 10.1002/14651858.CD012069.pub2.
5
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.患有共病抽动障碍的儿童注意力缺陷多动障碍(ADHD)的药物治疗。
Cochrane Database Syst Rev. 2018 Jun 26;6(6):CD007990. doi: 10.1002/14651858.CD007990.pub3.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Diagnosis and management of dental caries throughout life.一生当中龋齿的诊断与管理。
NIH Consens Statement. 2001;18(1):1-23.
9
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.一项关于哌甲酯、右旋苯丙胺和托莫西汀治疗儿童及青少年注意力缺陷多动障碍的有效性及成本效益的系统评价和经济学模型。
Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. doi: 10.3310/hta10230.
10
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.

引用本文的文献

1
Development of a Mobile-Based Personal Health Record for Pediatric Attention-Deficit/Hyperactivity Disorder Management: Protocol for a Study Based on Action Research Design.基于行动研究设计的儿童注意力缺陷多动障碍管理移动个人健康记录的开发:一项研究方案
JMIR Res Protoc. 2025 Apr 10;14:e60216. doi: 10.2196/60216.
2
Exploring correlations between Conners' Continuous Performance Test and subjective measures of attention deficit hyperactivity disorder symptoms in a paediatric clinical sample.探讨康纳斯连续操作测验与儿科临床样本中注意缺陷多动障碍症状的主观测量之间的相关性。
Singapore Med J. 2024 Oct 1;65(10):558-563. doi: 10.4103/singaporemedj.SMJ-2024-132. Epub 2024 Oct 4.
3
Gene-gene and gene-environmental interaction of dopaminergic system genes in Pakistani children with attention deficit hyperactivity disorder.
巴基斯坦患有注意力缺陷多动障碍儿童中多巴胺能系统基因的基因-基因和基因-环境相互作用
Saudi J Biol Sci. 2024 Aug;31(8):104045. doi: 10.1016/j.sjbs.2024.104045. Epub 2024 Jun 21.
4
Attention-Deficit/Hyperactivity Disorder Diagnoses in Finland During the COVID-19 Pandemic.注意力缺陷/多动障碍在 COVID-19 大流行期间的芬兰诊断情况。
JAMA Netw Open. 2024 Jun 3;7(6):e2418204. doi: 10.1001/jamanetworkopen.2024.18204.
5
Bisphenol-A and phthalate metabolism in children with neurodevelopmental disorders.儿童神经发育障碍中二酚 A 和邻苯二甲酸酯的代谢。
PLoS One. 2023 Sep 13;18(9):e0289841. doi: 10.1371/journal.pone.0289841. eCollection 2023.
6
Early detection of paediatric and adolescent obsessive-compulsive, separation anxiety and attention deficit hyperactivity disorder using machine learning algorithms.使用机器学习算法早期检测儿童和青少年的强迫症、分离焦虑症和注意力缺陷多动障碍。
Health Inf Sci Syst. 2023 Jul 22;11(1):31. doi: 10.1007/s13755-023-00232-z. eCollection 2023 Dec.
7
Generalizable prediction of childhood ADHD symptoms from neurocognitive testing and youth characteristics.从神经认知测试和青少年特征预测儿童 ADHD 症状的可推广性。
Transl Psychiatry. 2023 Jun 24;13(1):225. doi: 10.1038/s41398-023-02502-6.
8
Network Analysis of ADHD Symptoms and Cognitive Profiles in Children.儿童注意力缺陷多动障碍症状与认知特征的网络分析
Neuropsychiatr Dis Treat. 2023 May 18;19:1207-1219. doi: 10.2147/NDT.S409503. eCollection 2023.
9
Prediction of Attention-Deficit/Hyperactivity Disorder Diagnosis Using Brief, Low-Cost Clinical Measures: A Competitive Model Evaluation.使用简短、低成本临床测量预测注意缺陷多动障碍诊断:竞争性模型评估
Clin Psychol Sci. 2023 May;11(3):458-475. doi: 10.1177/21677026221120236. Epub 2022 Dec 22.
10
High rate of attention deficit hyperactivity disorder among children 6 to 17 years old in Southwest Ethiopia findings from a community-based study.埃塞俄比亚西南部 6 至 17 岁儿童注意缺陷多动障碍发生率高:一项基于社区的研究结果。
BMC Psychiatry. 2023 Mar 8;23(1):144. doi: 10.1186/s12888-023-04636-9.